Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Apricus Biosciences -- Ignore unavailable to you. Want to Upgrade?

To: apriluv who wrote (1934)	5/10/2016 11:31:46 PM
From: mokelumne river	Read Replies (1) \| Respond to of 2026

Thanks Aprilov. Shows that Pascoe is putting in effort to solve the Sandoz issue (whatever it is). Further, the consolidation statement is consistent with Pascoe's statement with regard to Ferring. Speaking of consolidation, I am sure many of us remain perplexed as to why Damaj initially decided to divide up the EU among so many partners. My suspicion was always that Damaj was afraid that a partner with too big a territory would decide to buy out his baby, Apricus. The result IMO was that no partner (Takeda specifically) initially had a big enough territory to justify mounting and maintaining a significant marketing campaign with a large enough market to generate reasonable revenues. Oh well. I think the Ferring move is a good one, despite that fact that I had never heard of Ferring before the Latin America license. Thanks again for following up, Aprilov.